Charting a Prosperous Path: PPMS Treatment Market to Achieve Over US$ 3.2 Billion by 2031

The global primary progressive multiple sclerosis (PPMS) treatment market has witnessed substantial growth in recent years, with projections indicating a promising outlook for the future. Characterized by the progressive deterioration of nerve cells' protective covering, PPMS presents unique challenges that require innovative solutions. This article delves into the key drivers, trends, players, and future prospects of the PPMS treatment market.

𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗮 𝘀𝗮𝗺𝗽𝗹𝗲 𝗼𝗳 𝘁𝗵𝗶𝘀 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗿𝗲𝗽𝗼𝗿𝘁 𝗮𝘁 (𝗨𝘀𝗲 𝗖𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝗠𝗮𝗶𝗹 𝗜𝗱 𝗳𝗼𝗿 𝗤𝘂𝗶𝗰𝗸 𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗲) -

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85270&utm_source=OpenPR_Ajay&utm_medium=OpenPR

𝗠𝗮𝗿𝗸𝗲𝘁 𝗢𝘃𝗲𝗿𝘃𝗶𝗲𝘄

In 2021, the PPMS treatment market was valued at US$ 828.4 million, and it is projected to exhibit a remarkable Compound Annual Growth Rate (CAGR) of 14.7% from 2022 to 2031. This growth can be attributed to various factors, including the rise in the geriatric population and the increasing prevalence of PPMS across the globe. Governments of both developed and developing countries are actively promoting awareness of available treatment options for multiple sclerosis, thereby contributing to market expansion.

𝗞𝗲𝘆 𝗙𝗮𝗰𝘁𝗼𝗿𝘀 𝗗𝗿𝗶𝘃𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 𝗚𝗿𝗼𝘄𝘁𝗵

Prevalence of PPMS: The prevalence of PPMS has been steadily increasing, affecting both men and women. In 2020, the National Multiple Sclerosis Society reported that approximately 2.8 million individuals were living with multiple sclerosis globally. This surge in cases drives the demand for effective drugs and medical interventions, propelling market growth.

Healthcare Expenditure: The continuous rise in healthcare expenditure, coupled with improved healthcare infrastructure, plays a vital role in expanding the PPMS treatment market. Various public and private organizations are actively promoting awareness about multiple sclerosis, thereby driving the industry forward.

Research and Development: Major players in the market are heavily investing in research and development activities to develop innovative drugs. While Roche's OCREVUS is currently available, ongoing R&D efforts aim to create more effective treatments. Numerous drugs are in clinical development, with some in advanced phases, hinting at the potential for breakthroughs in the near future.

𝗕𝘂𝘆 𝘁𝗵𝗶𝘀 𝗣𝗿𝗲𝗺𝗶𝘂𝗺 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 | 𝗜𝗺𝗺𝗲𝗱𝗶𝗮𝘁𝗲 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 𝗔𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 𝗮𝘁 -

https://www.transparencymarketresearch.com/checkout.php?rep_id=85270<ype=S&utm_source=OpenPR_Ajay&utm_medium=OpenPR

𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗗𝗶𝘀𝘁𝗿𝗶𝗯𝘂𝘁𝗶𝗼𝗻 𝗖𝗵𝗮𝗻𝗻𝗲𝗹𝘀

The PPMS treatment market is segmented into approved drugs and pipeline drugs based on drug type. Currently, Roche's OCREVUS dominates the approved drugs segment, while over 15 drugs are in various stages of clinical trials, suggesting a vibrant pipeline segment.

In terms of distribution channels, retail pharmacies lead the way due to favorable health reimbursement policies. The growth of online platforms in the pharmaceutical sector has also led to an upsurge in online distribution, making e-commerce a rapidly growing channel.

𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗢𝘂𝘁𝗹𝗼𝗼𝗸

North America holds a significant market share, driven by a high prevalence of PPMS in the United States and a growing demand for therapeutic drugs. Asia Pacific, particularly India and China, is poised to register the highest CAGR during the forecast period due to an increasing awareness of PPMS treatment options and improving healthcare infrastructure.

𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗰𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝘁𝗵𝗶𝘀 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗿𝗲𝗽𝗼𝗿𝘁 𝗮𝘁 -

https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=85270&utm_source=OpenPR_Ajay&utm_medium=OpenPR

𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀 𝗮𝗻𝗱 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁𝘀

Prominent players in the PPMS treatment market include F. Hoffmann-La Roche Ltd., Sanofi, Mapi Pharma Ltd., Atara Biotherapeutics, Takeda Pharmaceuticals International, Inc., AB Science, and Mallinckrodt. These companies are actively engaged in research, development, and clinical trials to enhance the quality of life for PPMS patients.

𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗙𝘂𝘁𝘂𝗿𝗲 𝗣𝗿𝗼𝘀𝗽𝗲𝗰𝘁𝘀

The PPMS treatment market's future is characterized by innovation and a focus on improving patients' lives. Ongoing research, emphasis on R&D activities, and a growing array of pipeline drugs indicate a promising path forward. The collaborative efforts of organizations like the International Progressive MS Alliance exemplify the dedication to finding effective treatments for PPMS and enhancing patients' quality of life.

𝗠𝗼𝗿𝗲 𝗧𝗿𝗲𝗻𝗱𝗶𝗻𝗴 𝗥𝗲𝗽𝗼𝗿𝘁𝘀 𝗯𝘆 𝗧𝗿𝗮𝗻𝘀𝗽𝗮𝗿𝗲𝗻𝗰𝘆 𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 -

Amniotic Membrane Market

https://www.globenewswire.com/en/news-release/2022/08/08/2494153/0/en/Amniotic-Membrane-Market-Attracts-Notable-Business-Avenues-with-Rising-Prevalence-of-ophthalmic-disorders-Says-TMR-Review.html

Joint Pain Injections Market

https://www.globenewswire.com/en/news-release/2022/08/08/2494104/0/en/Joint-Pain-Injections-Market-Expands-due-to-Rising-Prevalence-of-Knee-related-Diseases-States-TMR-Study.html

About Us Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Contact Us

Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.